2023 will be a pivotal year for biosimilar success or failure. Health care expert Fred Goldstein sits down with Stanton Mehr of Biosimilars Review & Report, to discuss what lies in store for biosimilars and AMCP’s biosimilar initiatives this year.
On Jan. 22, 2024, the Department of Health and Human Services (HHS) issued a
letter to Medicare plans, health insurance issuers, and State Medicaid and CHIP
programs (Letter) and a set of Frequently Asked Questions (FAQs) outlining how
plans and issuers can make sure they meet their contraception coverage
obligations.
During this sponsored webinar, we will overview Alzheimer's Disease (AD), discuss key considerations during the patient journey, and examine the potential impact of early intervention on the financial burden associated with AD.
Health care expert Fred Goldstein, host of the AMCP Podcast Series — Listen Up! sits down with Jennifer Graff, Senior Director of Professional Affairs at AMCP, to discuss trends to be watching regarding digital therapeutics and managed care pharmacy in 2023.
The Inflation Reduction Act (IRA) requires the establishment of a new Medicare Part D
manufacturer discount program (MDP) beginning Jan. 1, 2025 and requires participating
manufacturers to enter into agreements with CMS by Mar. 1, 2024 in order to participate in the
MDP in 2025. Agreements will be valid for not less than one year and automatically renew
unless terminated by CMS or the manufacturer.
The Academy of Managed Care Pharmacy (AMCP) supports an abbreviated licensure pathway for the approval of biosimilar biologic drug therapies.
On Feb. 1, the Final Rule, titled Medicare and Medicaid Programs; Policy and Technical
Changes to the Medicare Advantage, Medicare Prescription Drug Benefit, Program of AllInclusive Care for the Elderly (PACE), Medicaid Fee-For-Service, and Medicaid Managed Care
Programs for Years 2020 and 2021, was published in the Federal Register.
Health care expert Fred Goldstein, host of the AMCP Podcast Series — Listen Up!, sits down with Susan Cantrell, AMCP CEO, to discuss the significance of the recent passage of the Pre-approval Information Exchange (PIE) Act of 2022.
